INTRODUCTION
Laser-assisted tattoo removal is an increasingly common practice [1] . Traditional laser tattoo removal consists of single-pass laser treatments, spaced 7-8 weeks apart, for a total of 7-10 sessions [1] . A major limiting factor of laser assisted tattoo removal is the development of epidermal opaque whitening that results from the laser interaction with the tattoo pigment. The ink particles in the tattoo absorb the high optical energy of the laser pulse and transfer the energy to surrounding tissue, leading to the formation of microscopic cavitation bubbles, which appear as whitening or frosting over the tattoo [2] . The opaque white layer is highly optically scattering and prevents multiple laser passes, as light can no longer penetrate sufficiently to interact with the pigment. While the R20 pass system, whereby a patient waits 20 minutes between each pass for the whitening to resolve, may provide faster clearance, it is impractical in the clinical setting and carries the risk of increased epidermal injury [3] . The use of perfluorodecalin (PFD), which dissolves gases and provides optical clearance has demonstrated efficacy in facilitating multiple passes in the same treatment session [4] [5] [6] .
PFD is an inert colorless fluorocarbon liquid that dissolves gases and acts as an optical clearing agent [7, 8] . Since the partial pressure of gas in laser-induced microcavitation bubbles is well above the partial pressure of atmospherically equilibrated PFD, the diffusion of gas follows a pressure gradient from micro-bubbles into liquid PFD [4] . PFD decreases optical scatter near the skin's surface so that an increased fluence is delivered to deeply residing ink particles [5] . Furthermore, the silicone patch prevents evaporation of liquid PFD and enhances epidermal protection as direct contact between skin, the silicone material, and PFD allows for more efficient transfer of heat away from the skin's surface [5, 6] .
Previous studies have demonstrated that the PFDinfused patch facilitates rapid multi-pass treatments with Q-switched and Picosecond lasers and clears tattoos faster than conventional methods. The PFD patch enabled subjects to tolerate higher fluences with each pass. In addition, use of the PFD patch was well tolerated compared to conventional laser treatment, with subjects experiencing fewer and less severe AEs related to epidermal injury, such as erythema and edema [6] . The United States Food and Drug Administration (FDA) approved the PFD-infused silicone patch in 2015 as an accessory to tattoo removal using 755-nm Q-switched laser in patients with Fitzpatrick skin types I-III. The FDA clearance was expanded in 2017 to include picosecond lasers but still limited to patients with Fitzpatrick skin types I-III.
To date, the efficacy and safety of the PFD patch has only been reported in patients with Fitzpatrick skin types I-III [5, 6] . Moreover, the majority of published data for newer laser devices such as the picosecond laser, is based on patients with skin types II-IV [9] [10] [11] , despite the need to improve treatment outcomes in patients with dark skin, who have an increased risk of complications from laser tattoo removal, including dyspigmentation and scarring [12] . In this study, we report the safety of the PFD patch when used with Qswitched and Picoway lasers in patients with Fitzpatrick skin types IV-VI.
METHODS

Subject Selection
This retrospective single-center chart review investigated safety outcomes of laser assisted tattoo removal with the use of the PFD patch in patients with Fitzpatrick types IV-VI. Fourteen adult patients, aged 23-66, were treated with the PFD patch in conjunction with either a Q-Switched or a Picosecond laser. Tattoos contained black, blue, red, green, purple, and pink ink (Table 1) .
Study Design
Adverse events (AEs) were assessed immediately following the procedure and at a 6-8 week follow-up visit. Acute adverse events were defined as erythema, edema, pain, and crusting. Long-term adverse effects such as blister formation, post-inflammatory hyper/hypopigmentation, scarring, and textural changes were also evaluated. The secondary endpoint measured efficacy, defined as the ability to do more than a single-pass in each treatment session.
Treatment Protocol
Lidocaine HCl 1% with or without epinephrine 1:100,000 was injected at the treatment site for all subjects. Liquid PFD from the device packaging using foam-tipped swabs was applied to the treatment area, and then the patch was immediately placed over the treatment area. Each tattoo was then treated conventionally using either the Spectra Q-switched Nd:YAG laser at 1064 nm (Lutronic, South Korea) or the PicoWay Nd:YAG laser at 532, 785, and 1064 nm (Syneron-Candela, Israel) with spot size ranging from 3 to 10 mm and fluence ranging from 0.25-12.0 J/cm 2 . The patch was removed immediately after treatment. The tattoos were treated at the maximumtolerated fluence as determined by epidermal whitening. Up to three passes were performed in accordance with observed clinical signs and patient-reported symptoms.
RESULTS
The PFD patch and liquid PFD were used with the picosecond (532, 785, 1064 nm) and the Q-switched Nd: YAG (1064 nm) lasers (Figure 1 ). Ten (71%) patients underwent two or more treatment sessions with the PFD patch, and 4 (29%) patients underwent a single treatment session. All 14 (100%) subjects reported no immediate or long-term adverse effects with the use of the PFD patch in conjunction with the picosecond (532, 785, 1064 nm) and the Q-switched Nd:YAG (1064 nm) lasers. Ten patients (nine with type V skin; one with type IV skin) were followed for 3-months after their last treatment; none had developed hyper or hypopigmentation at the treatment site. There were no adverse events with the use PFD patch when treating tattoos containing blue, black, red, green, purple, and pink ink. Nine (64%) patients tolerated multiple pass treatments. Treatment through the patch allowed higher treatment fluence in all subjects relative to conventional treatment without the patch. 
SAFETY OF PFD PATCH IN FITZPATRICK SKIN TYPES IV-VI
DISCUSSION
Patients with Fitzpatrick skin types IV-VI are at increased risk of adverse events due to increased epidermal melanin content and reactive fibroblast responses [13] . The liquid PFD and the patch may enhance safety and efficacy through their protective effects on the epidermis, by reducing optical scatter and conducting heat away from the skin surface. Thermal protection of the epidermis is further enhanced by the transparent silicone material, as well as the high heat capacity of PFD relative to air [5] . In addition, air is excluded from the patch-skin interface providing good thermal coupling from the epidermis through the PFD into the silicone, enabling it to serve as a "heat sink" [5] . Subjects in previous studies reported no immediate or delayed-onset AEs associated with epidermal injury (e.g., erythema, edema) suggesting that use of the PFD patch may lead to improved healing after treatment [6] .
This study also demonstrated safety and efficacy of the PFD patch when used in the laser-assisted removal of numerous colored inks (Figure 1 , Inset A and B; E and F). Previously reported studies have primarily been conducted on tattoos composed of black or dark blue ink. Because the refractive indices of PFD and silicone are well matched to that of the epidermis over a range of wavelengths applicable for tattoo removal ($600-1,064 nm), it is plausible that PFD patch provided similar optical clearing abilities when used with these wavelengths [5, 6, 14] .
This study further supports safety outcomes with use of the PFD patch in patients with darker Fitzpatrick skin types. It also demonstrated that the PFD patch is safe in the treatment of various colored tattoos. Limitations to this study include the lack of long-term safety data and small sample size. Efficacy of the PFD patch was not assessed as a primary endpoint.
CONCLUSION
The PFD and the silicone patch provide epidermal production by acting as a "heat sink," which mitigates laser-associated adverse effects. In our experience, multiple-pass treatments with the PFD patch are safe and well tolerated when used with picosecond and Q-switched Nd: YAG lasers in patients with Fitzpatrick IV-VI skin. A split tattoo study comparing the picosecond laser with the PFD patch versus the picosecond laser alone is of interest in further determining efficacy. While there is no consensus or protocol for reducing complications of laser assisted tattoo removal in darker skin types, the PFD patch may have a role in improving outcomes by reducing the risk of dyspigmentation and scarring.
